Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Rhea-AI Summary
Fortress Biotech (Nasdaq: FBIO) announced that Lindsay A. Rosenwald, M.D., Chairman, President and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 12:30pm ET.
According to Fortress Biotech, the session is virtual and registration is available via the conference website.
Positive
- None.
Negative
- None.
News Market Reaction – FBIO
In the May 4 session, FBIO gained 2.15%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Access expansion news | Positive | -3.9% | Journey Medical expanded Emrosi payer access to over 150 million lives. |
| Mar 31 | Full-year earnings | Positive | -11.5% | Fortress reported 2025 results with FDA approval and major asset monetizations. |
| Mar 30 | PRV sale proceeds | Positive | +3.3% | Cyprium closed $205M PRV sale; Fortress expected over $100M proceeds. |
| Mar 25 | Subsidiary earnings | Positive | -3.7% | Journey Medical posted higher 2025 revenues, better margins and narrowed loss. |
| Mar 18 | Earnings date notice | Neutral | +1.3% | Journey Medical scheduled its year-end 2025 earnings release and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and financial updates have often seen negative or muted next-day price reactions, with only one clear alignment between upbeat news and a positive move.
Over the last few months, Fortress-related news has focused on monetizing assets, improved profitability, and partner-driven growth. Key items include a PRV sale with expected liquidity, 2025 financial results with asset monetizations, and royalty and milestone structures tied to ZYCUBO and partner programs. Several Journey Medical updates highlighted revenue growth and improved margins. Despite generally constructive narratives, price reactions have frequently been negative, showing a tendency for good news to meet selling pressure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET.
To register for the conference, visit https://hcwevents.com/royalty-company-conference.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
